Abstract: Compositions useful for carrying physiologically active agents such as therapeutic agents through skin and other body membranes comprising the agent and an effective, non-toxic amount of a compound having the structural formula ##STR1## wherein R' is H or a lower alkyl group, m is 3-7, N is 0-17 and R is --CH.sub.3, phenyl or substituted phenyl or ##STR2## with the proviso that if m is 3 and R is --CH.sub.3, then n is not 0-6.

Abstract: In a method of synthesis of 1-substituted azacycloalkan-2-ones with primary alkyl halides and aralkyl halides as alkylating agents, the improvement comprising carrying out the N-alkylation in the presence of a phase transfer catalyst having the structural formula ##STR1## where X is suitable anion; and R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each alkyl or aralkyl groups having 1-18 carbon atoms, or R.sub.2, R.sub.3 and R.sub.4 can form a part of a heterocyclic ring, with the proviso that the combined total of carbon atoms is between 16 and 40.

Abstract: Compositions useful for carrying physiologically active agents such as therapeutic agents through skin and other body membranes comprising the agent and an effective, non-toxic amount of a compound having the structural formula ##STR1## wherein R' is H or a lower alkyl group, m is 3-7, N is 0-17 and R is --CH.sub.3, phenyl or substituted phenyl or ##STR2## with the proviso that if m is 3 and R is --CH.sub.3, then n is not 0-6.

Abstract: Compositions useful for carrying physiologically active agents such as therapeutic agents through skin and other body membranes comprising the agent and an effective, non-toxic amount of a compound having the structural formula ##STR1## wherein R' is H or a lower alkyl group, m is 3-7, N is 0-17 and R is --CH.sub.3, phenyl or substituted phenyl or ##STR2## with the proviso that if m is 3 and R is --CH.sub.3, then n is not 0-6.

Abstract: In a method for administering systemically active agents including therapeutic agents through the skin or other body membranes of humans and animals typically in the form of a transdermal device or formulation, the improvement comprising the use therewith of an effective amount of a membrane penetration enhancer having the structural formula. ##STR1## wherein R is H or a lower alkyl group, m is 5-7 and n is 0-17.

Abstract: Pharmaceutical compositions containing triethylenetetramine (trien) useful in treating skin disorders. Trien may be used alone to treat inflammation of the skin or may be combined with additional anti-inflammatory, anti-infective or antimitotic agents in the treatment of skin disorders such as acne, psoriasis, seborrhea and dermatitis. Trien also forms a clear solution or gel with zinc pyrithione.

Abstract: A method for temporarily reducing pain in animals including humans, and especially pain associated with gastrointestinal dysfunction, by administering to an animal having pain an effective, pain reducing amount of dextromethorphan, preferably as the hydrobromide.

Abstract: Compositions useful for carrying physiologically active agents such as therapeutic agents through skin and other body membranes comprising the agent and an effective, non-toxic amount of a compound having the structural formula ##STR1## wherein R' is H or a lower alkyl group, m is 3-7, N is 0-17 and R is --CH.sub.3, phenyl or substituted phenyl or ##STR2## with the proviso that if m is 3 and R is --CH.sub.3, then n is not 0-6.

Abstract: There is disclosed a method of improvement of dyeing fibers by utilizing in the dyeing process, an effective, dye-enhancing amount of a textile auxiliary having the structural formula ##STR1## wherein R' is H or a lower alkyl group having 1-4 carbon atoms, n is O or a positive integer from 1-11 and R is an alkyl group (straight or branch chain) having 1-18 carbon atoms or aryl group, e.g., phenyl. The compounds disclosed herein enhance dye penetration of fibers and allow the dyeing process to take place at lower temperatures in less time.

Abstract: There is disclosed a method of treatment of inflammation in humans and animals comprising contacting the inflamed area with an effective, anti-inflammatory amount of 1-dodecylazacycloheptan-2-one.

Abstract: The disclosure describes a method for selectively inhibiting thromboxane biosynthesis with Burimamide, a compound previously known to be a histamine H.sub.2 -receptor blocker. The discovery is useful in the treatment of a number of cardiovascular and inflammatory diseases in which thromboxane biosynthesis is involved.

Abstract: A therapeutic composition comprising a topically administrable ophthalmic pharmaceutical carrier and colchicine. The foregoing composition temporarily alleviates the symptoms of glaucoma when topically administered to the eye.

Abstract: A therapeutic composition comprising a topically administrable ophthalmic pharmaceutical carrier and vinblastine. The fore-going composition temporarily alleviates the symptoms of glaucoma when topically administered to the eye.

Abstract: The disclosure describes a method for selectively inhibiting thromboxane biosynthesis with Burimamide, a compound previously known to be a histamine H.sub.2 -receptor blocker. The discovery is useful in the treatment of a number of cardiovascular and inflammatory diseases in which thromboxane biosynthesis is involved.

Abstract: A process for inhibiting platelet aggregation or thrombus formation by the addition of a member selected from the group consisting of a compound of the formula: ##STR1## WHEREIN X is an alkyl or alkenyl chain having 2-8 carbon atoms, one of which carbon atoms may be in the form of a carbonyl group, Y is H, alkyl, dialkylaminoethyl, aryl, aralkyl or aryl and aralkyl substituted with one or more R, and R is H, lower alkyl, lower alkoxy, halogen, CF.sub.3, NO.sub.2, OH, CN, COOR.sub.1, ##STR2## NHCOR.sub.1, NR.sub.1 R.sub.2 or ##STR3## where R.sub.1 and R.sub.2 are each selected from the group consisting of H and lower alkyl; R, R.sub.1 and R.sub.2 being the same or different, T is selected from the group consisting of O, NH, S and CH.sub.2 with the proviso that only one T is O, Z is 0 or 1 and n is 0-5; and pharmaceutically acceptable salts thereof, to in vivo and in vitro platelet systems.

Abstract: A process for inhibiting platelet aggregation or thrombus formation by the addition of a member selected from the group consisting of a compound of the formula: ##STR1## WHEREIN X is an alkyl or alkenyl chain having 2-8 carbon atoms, one of which carbon atoms may be in the form of a carbonyl group, Y is H, alkyl, dialkylaminoethyl, aryl, aralkyl or aryl and aralkyl substituted with one or more R, and R is H, lower alkyl, lower alkoxy, halogen, CF.sub.3, NO.sub.2, OH, CN, COOR.sub.1, ##STR2## NHCOR.sub.1, NR.sub.1 R.sub.2 or ##STR3## where R.sub.1 and R.sub.2 are each selected from the group consisting of H and lower alkyl; R, R.sub.1 and R.sub.2 being the same or different and n is 0-5; and pharmaceutically acceptable salts thereof, to in vivo and in vitro platelet systems.

Abstract: There is disclosed a shelf-stable microbicidal composition containing no water and including an ene-diol compound, a specific catalytic metal compound, and a propellant suitable for dispensing the ingredients from an aerosol container, with at least one of the ene-diol compound and the catalytic metal compound not in solution. Oxidation of the ene-diol compound catalyzed by the metal compound produces a microbicidal effect.

Abstract: A method for treating schizophrenia and a method and composition for potentiating the beneficial effects and reducing the side effects of neuroleptic drugs. Schizophrenia is treated with a GABA-like compound such as Lioresal. Neuroleptic drugs are potentiated by coadministering to a schizophrenic a neuroleptic drug and a GABA-like drug such as Lioresal.

Abstract: There is disclosed a topical antibacterial composition and method for topical antibiotic treatment. The method involves contacting the skin of a human or animal with an effective amount of a composition containing an antibiotic of the erythromycin family and 2-pyrrolidone or an N-lower alkyl-2-pyrrolidone. The preferred use of the foregoing composition and method is in the treatment of acne.

Abstract: A method for treating schizophrenia and a method and composition for potentiating the beneficial effects and reducing the side effects of neuroleptic drugs. Schizophrenia is treated with a GABA-like compound such as Lioresal. Neuroleptic drugs are potentiated by coadministering to a schizophrenic a neuroleptic drug and a GABA-like drug such as Lioresal.